Atrial fibrillation is a kind of arrhythmia, i.e. irregular beating of the heart. It can start with sparse segments of arrhythmic beating, but can eventually lead to severe complications. While most cases of atrial fibrillation have no clear symptoms, most people experience shortness of breath, fainting, palpitations, and/or pain in the chest. It can complicate into heart failure or stroke. Another complication of atrial fibrillation is dementia caused by the lack of oxygen in the brain due to the irregular heartbeats.
The global atrial fibrillation market is exhibiting a CAGR of 13.40% between 2013 and 2019. The market was valued at US$6.1 bn in 2012. By the end of 2019, this market is expected to reach US$14.8 bn. The key players that are expected to act through this period are Johnson and Johnson Ltd., St. Jude Medical, Inc., Sanofi Aventis, Endoscopic Technologies, Inc., CardioFocus, Inc., Bristol-Myers Squibb Corporation, Boston Scientific Corporation, Boehringer Ingelheim GmbH, Biosense Webster, Inc., and AtriCure, Inc.
Browse the full Global Atrial Fibrillation Market report at http://www.mrrse.com/atrial-fibrillation-market
CDC Findings Concur with Global Atrial Fibrillation Market Growth
In findings released by the Centers for Disease Control in the U.S., about 2.66 mn people suffered from atrial fibrillation in 2010. Given the role played by current factors such as sedentary lifestyles and increasing levels of stress, the CDC suggests that this number could go up to 12 mn by 2050. As such, the global atrial fibrillation market is expected to rise at a faster rate in order to keep up with the increasing number of patients suffering from the problem.
The market is further bolstered by the increasing number of individuals with high disposable incomes. This has presented a scenario where consumers are able to spend more on healthcare benefits and other relevant areas. At the same time, the healthcare industries in Europe and North America are already highly advanced and thus able to offer better solutions for atrial fibrillation. As for the developing economies, the global atrial fibrillation market is being boosted by the rapid rate of improvements in the healthcare infrastructure.
North America Leads Global Atrial Fibrillation Market
From a geographical perspective, it is witnessed that North America dominated the global atrial fibrillation market in 2012. Meanwhile, the fastest growth rate in the forecast period is attributed to Asia Pacific, owing to rapid developments and the increase in medical tourism. Additionally, the number of cases of atrial fibrillation being registered in APAC nations such as China and India is increasing, further boosting the global atrial fibrillation market.
Pharmacological Treatments Dominate Global Atrial Fibrillation Market
Based on treatment method, the global atrial fibrillation market is segmented into pharmacological and non-pharmacological treatments. Amongst these, the market was led by the segment of pharmacological treatments in 2012, due to the consistent administration of these treatments to the patients along with non-pharmacological treatments.
It is thus expected for pharmacological treatments to occupy 55.0% of the market by 2019. This is possible through the increase in the use of new anticoagulants, including dabigatran and rivaroxaban. The global atrial fibrillation market is also expected to be propelled by the release of new drugs such as Pradaxa, Vernakalant, and NTC-801.